If you have been reading about aminoisobutyric acid and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-04-30. Where a claim depends on a specific study, the study is described rather than over-claimed.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Unmodified peptide backbone |
| Molecular mass | approx. 4,813 Da | 39-residue linear chain |
| Receptor targets | GIP and GLP-1 | Dual agonist activity |
| Route | Subcutaneous injection | Weekly administration interval |
| Elimination half-life | approx. 5 days | Supports weekly dosing schedule |
该化合物的名称与结构由国际非专利名称体系统一维持，不同文献中出现的同义写法主要在拼写顺序或盐形式描述上不同。研究者通常通过受体结合实验、细胞内环磷酸腺苷积累测定以及动物模型来确认其双激动活性。相当一部分分子层面的细节——例如两条受体通路之间的信号交叉作用——尚处于开放问题状态。
当前公开资料把 tirzepatide 归为肠促胰素类受体双重激动剂。它并非激素天然变体，而是经过序列改造的工程化肽。其分子量、等电点与疏水性等基础参数已在药典和化学数据库中收录，可作为分析检测和质量研究的参照。
Tirzepatide 是一种由 39 个氨基酸组成的合成肽，分子结构上以 GIP 序列为骨架并引入脂肪酸侧链修饰，使其能够同时与葡萄糖依赖性促胰岛素多肽（GIP）受体和胰高血糖素样肽-1（GLP-1）受体结合。这种双重激动特性使它在同类肽类药物中区别于选择性 GLP-1 受体激动剂。该分子最早由一家制药公司在 2010 年代报道，随后进入糖尿病与体重管理领域的临床研究。
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
Pharmacologically, tirzepatide activates two distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Binding at each target triggers cyclic AMP accumulation and downstream signaling in pancreatic beta cells, adipose tissue and the central nervous system. Because the two pathways overlap only partially, the combined effect on insulin secretion, glucagon suppression and appetite signaling differs from that of selective single-receptor compounds. Affinity is not equal across the two targets, and the clinical meaning of that imbalance remains an area of active study.
Clinical research programs have evaluated tirzepatide in adults with type 2 diabetes and in adults with obesity or excess weight. Trials generally reported reductions in glycated hemoglobin and body weight across treatment periods of several months. Since these studies enrolled defined populations under controlled conditions, the findings describe group averages rather than individual outcomes. Open questions include the durability of effects after treatment stops, variation among subgroups, and the long-term consequences of sustained dual receptor stimulation. Published trial summaries should be consulted for exact measurements rather than secondary accounts.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its backbone derives from the native glucose-dependent insulinotropic polypeptide sequence, altered at several positions to resist enzymatic cleavage. A fatty diacid group attached through a linker extends plasma residence time by promoting reversible binding to serum albumin. The molecule carries a net negative charge near physiological pH and has a reported molecular weight close to 4813 daltons. These features separate it from shorter incretin analogs and account for its prolonged dosing interval.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
In this instance reversal of paralysis will not occur until the damaged terminal axons at the neuromuscular junction have recovered, this may take days or weeks. The drug may also be used for reversal of neuromuscular blockade at the end of a surgical procedure.
Chell is the player-character in both Portal games. She is a silent protagonist outside of small grunts during physical tasks. Very little truthful information is known about Chell; while GLaDOS makes many statements to Chell's background and history, GLaDOS herself admits she is unreliable. The only consistent fact that is used through the series is that Chell's parents gave her away. Whether they did it intentionally or not is unknown. Chell's appearance is modeled after Alésia Glidewell
Insulin degludec is an ultralong-acting basal insulin analogue developed by Novo Nordisk. Ultralong-acting insulins are a kind of insulin that can work up to a week. It is administered through subcutaneous injection to assist in controlling blood sugar levels in individuals with diabetes. Its duration of action lasts up to 42 hours, which is significantly longer than other long-acting insulins, such as insulin glargine and insulin detemir, which typically last 18 to 26 hours. This makes insulin degludec a once-daily basal insulin, providing a steady insulin level, in contrast to fast-acting bolus insulins. Insulin degludec is a modified form of insulin in which a single amino acid is deleted compared to human insulin. It is also conjugated to hexadecanedioic acid via a gamma-L-glutamyl spacer at the amino acid lysine at position B29. It is included on the World Health Organization's List of Essential Medicines as an alternative to insulin glargine. In 2022, it was the 138th most commonly prescribed medication in the United States, with more than 4 million prescriptions. Insulin Degludec is currently only produced by Novo Nordisk under the name Tresiba. It is also available under a generic label until the start of 2026.
Staff Department (Deputy Theater Command Grade); Training Bureau (Division Leader Grade); Intelligence Bureau (Division Leader Grade), led by Zhang Xiaoqi; Political Work Department (Deputy Theater Command Grade): led by Director Lieutenant general Gao Wei; Propaganda Bureau (Division Leader Grade); Soldier and Civilian Personnel Bureau (Division Leader Grade); Discipline Inspection Commission (Deputy Theater Command Grade); Logistics Department (Corps Leader Grade); Equipment Department (Corps Leader Grade). Being of Theatre Command Grade, the People's Armed Police is led by a full General.
In the United States, fire and hot liquids are the most common causes of burns. Of house fires that result in death, smoking causes 25% and heating devices cause 22%. Almost half of injuries are due to efforts to fight a fire. Scalding is caused by hot liquids or gases and most commonly occurs from exposure to hot drinks, high temperature tap water in baths or showers, hot cooking oil, or steam. Scald injuries are most common in children under the age of five and, in the United States and Australia, this population makes up about two-thirds of all burns. Contact with hot objects is the cause of about 20–30% of burns in children. Generally, scalds are first- or second-degree burns, but third-degree burns may also result, especially with prolonged contact. Fireworks are a common cause of burns during holiday seasons in many countries. This is a particular risk for adolescent males. In the United States, for non-fatal burn injuries to children, white males under the age of 6 comprise most cases. Thermal burns from grabbing/touching and spilling/splashing were the most common type of burn and mechanism, while the bodily areas most impacted were hands and fingers followed by head/neck.
Sources: en.wikipedia.org
== Further reading == Virginia Ott (November 1976). Man with a Million Ideas: Fred Jones, Genius/Inventor. Lerner Publications Company. ISBN 978-0-822-50761-1. Gloria M. Swanson, Margaret V. Ott (1994). I've Got an Idea: The Story of Frederick McKinley Jones (reprint ed.). Lerner Publishing Group. p. 95. ISBN 0-82259-662-8.
Starring a principal cast of Josh Hartnett, Bruce Willis, Lucy Liu, Stanley Tucci, and Ben Kingsley, the film garnered mixed reception. David Mattin of BBC wrote: "Kingsley and Freeman shine individually, but their inevitable, climactic clash of heads lacks force. Like its leading man [Hartnett], this movie presents a charming façade with nothing much underneath." Next, Freeman portrayed himself in the low-budget comedy 10 Items or Less opposite Paz Vega. Two weeks after its theatrical release, 10 Items or Less was made available for download from ClickStar, a film distribution company that Freeman co-founded that year. In 2007, Freeman reprised his role as God in Evan Almighty, a sequel to 2003's Bruce Almighty, with Steve Carell. Evan Almighty was a box-office failure and negatively received; The Guardian critic wrote: "A cast full of people who have been frequently funny elsewhere flounder in this deluge of sentimentality and CGI. Avoid like the Ten Plagues." The drama Feast of Love was Freeman's second release of 2007. It is based on the 2000 novel The Feast of Love by Charles Baxter, about a group of friends living in suburban Oregon who come into contact with a free spirit who changes their outlook on life; Peter Bradshaw of The Guardian sarcastically remarked that it was great to see Freeman in a challenging role. Freeman had a supporting part in Gone Baby Gone (2007), a mystery thriller that was also Ben Affleck's directorial debut. Adapted from the 1998 novel of the same name by Dennis Lehane, Freeman plays Captain Jack Doyle of the Boston Police Department.
Chitosan can be spun directly into a fiber, which can be used to make dressings such as gauze. An example is HemCon OneStop Vascular, approved in the US in 2003. Chitosan can be incorporated into ordinary fabrics like gauze, creating chitosan-impregnated gauze which is cheaper than chitosan fiber. Examples include HemCon Guardacare PRO (ChitoGauze, FDA approved 2006), Celox Gauze (FDA approved 2006). Chitosan can be incorporated into a hydrogel. Such dressings have also been found useful as burn dressings, and for the treatment of chronic diabetic wounds and hydrofluoric acid burns.
==== Robust transport networks ==== According to FAO, robust transport networks can prevent or limit increases in travel time – and consequent impacts on food costs – when an adverse event limits or prevents access to critical network links. For example, flooding, whether from flash floods or from longer-term stagnant flooding, reduces the connectivity of any transport network, impacting the movement of people, goods and societal functioning in general. Damage from flooding can indirectly affect larger areas for a longer period of time, such as when there are traffic delays and congestion on alternative routes, increased journey distances/durations, increased fuel consumption and associated greenhouse gas (GHG) emissions. Due to climate change, transport networks are increasingly being exposed to extreme weather events. A study on the transport networks of 90 countries finds that where food is transported more locally and where the network is denser – such as in high-income countries and densely populated countries like China, India, Nigeria and Pakistan –, systematic disturbances have a much lower impact. Conversely, low-income countries have much lower levels of transport network resilience, although some exceptions exist. The study further simulates the effect of potential disruptions – namely floods – to food transport networks which illustrate that the loss of network connectivity that results when links become impassable potentially affects millions of people.
A coalition known as "No G7" organised demonstrations in Geneva against the summit. The coalition included groups such as BDS, trade unions including the Swiss Union of Public Service Personnel, and political groups including SolidaritéS and the New Anticapitalist Party. The coalition criticised the G7 as an "illegitimate and outdated" forum of concentrated political and economic power and issued demands relating to relating to the conflicts in the Levant and Iran, an end to trade relations with Israel, opposition to US military bases, workers' rights, gender equality and LGBTQ rights. The protest on 14 June 2026 coincided with the annual Swiss feminist strike and was presented by organisers as a call to build an internationalist response to the summit. The Canton of Geneva authorised a demonstration on the right bank of the city between Genève-Cornavin railway station and the international organisations district, but refused permission for a protest camp. A motion in the Grand Council of Geneva calling for a ban on demonstrations during the summit was rejected by 55 votes to 42. Geneva authorities expected up to 50,000 demonstrators for the anti-G7 protest. Businesses in central Geneva prepared for possible unrest by boarding up shopfronts. On 14 June, about 20,000 people joined the No G7 march in Geneva according to the police, while organisers placed attendance around 60,000.
Sources: en.wikipedia.org
==== Inflammation and allergy ==== 12-HHT stimulates chemotactic responses in mouse bone marrow mast cells, which naturally express BLT2 receptors, as well as in Chinese hamster ovary cells made to express these receptors by transfection. These findings suggest that the 12-HHT/BLT2 receptor pathway may support the pro-inflammatory (i.e. chemotactic) actions of the LTB4/BLT1 pathway. On the other hand, the immortalized human skin cell line HaCaT expresses BLT2 receptors and responds to ultraviolet B (UVB) radiation by generating toxic reactive oxygen species which in turn cause the HaCaT cells to die by activating apoptotic pathways in a BLT2 receptor-dependent reaction. Topical treatment of mouse skin with a BLT2 receptor antagonist, LY255283, protects against UVB radiation-induced apoptosis and BLT2-overexpressing transgenic mice exhibited significantly more extensive skin apoptosis in response to UVB irradiation. Furthermore, 12-HHT inhibits HaCaT cells from synthesizing interleukin-6 (IL-6), a pro-inflammatory cytokine associated with cutaneous inflammation, in response to UVB radiation. These results suggest that the 12-HHT/BLT2 axis can act to suppress inflammation by promoting the orderly death of damaged cells and blocking IL-6 production. Opposition between the pro-inflammatory LTB4/BLT1 and anti-inflammatory actions of the 12-HHT/BLT2 axes occurs in another setting.
=== Semi-skip chain === Alternates having one or two drive links between pairs of cutters, for performance in between that of full complement and skip arrangements. The terms used to describe chain arrangements can be confusing. Most modern chains do not have only cutter teeth and drive links. There are tie straps which separate the cutters from each other.
The Zydis formulations consist of a drug physically trapped in a water-soluble matrix (saccharine mixture and polymer), which is freeze dried to produce a product that dissolves rapidly when placed in mouth. The ideal candidate for Zydis technology should be chemically stable and insoluble and particle size preferably less than 50 micron.
==== Stress management ==== Although psychological stress is recognized as a risk factor for type 2 diabetes, the effect of stress management interventions on disease progression are not established. A Cochrane review is under way to assess the effects of mindfulness‐based interventions for adults with type 2 diabetes.
In the bones, estradiol accelerates ossification of cartilage into bone, leading to closure of the epiphyses and conclusion of growth. In the central nervous system, testosterone is aromatized to estradiol. Estradiol rather than testosterone is the most important feedback signal to the hypothalamus (especially affecting LH secretion). In many mammals, prenatal or perinatal "masculinization" of the sexually dimorphic areas of the brain by estradiol derived from testosterone programs later male sexual behavior.
Sources: en.wikipedia.org
It is a dual GIP and GLP-1 receptor agonist, frequently grouped with incretin-based peptide therapeutics. It is a peptide rather than a small molecule and is given by subcutaneous injection.
Selective agents engage only the GLP-1 receptor, whereas tirzepatide activates GIP and GLP-1 receptors simultaneously. This difference in receptor coverage is the principal pharmacological distinction emphasised in comparative reviews.
Downstream signalling is partly characterised, but the quantitative contribution of GIP versus GLP-1 receptor activation to metabolic outcomes is not settled. Review articles commonly flag this as an unresolved question rather than a settled finding.
It activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. This dual activity separates it from agents that act on only one of the two receptors. The relative contribution of each receptor to clinical effects remains an open area of study.